Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Onno W Akkerman

Showing results (11-20 of 115) with videos related to

Pageof 12
Sort By:
Infection|April 8, 2024
The agreement between bronchoalveolar lavage, bronchial wash and sputum culture: a retrospective studyAnne-Eva Post, Erik Bathoorn, Douwe F Postma, et al.
The European Respiratory Journal|September 14, 2019
Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the NetherlandsFajri Gafar, Natasha Van't Boveneind-Vrubleuskaya, Onno W Akkerman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 31, 2020
Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?Jan-Willem C Alffenaar, Onno W Akkerman, Hannah Yejin Kim, et al.
Antimicrobial Resistance and Infection Control|July 25, 2019
Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015Ivan S Pradipta, Natasha Van't Boveneind-Vrubleuskaya, Onno W Akkerman, et al.
Antimicrobial Agents and Chemotherapy|December 24, 2013
Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment responseOnno W Akkerman, Richard van Altena, Mathieu S Bolhuis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis TreatmentMarieke G G Sturkenboom, Noviana Simbar, Onno W Akkerman, et al.
The Journal of Infectious Diseases|March 6, 2019
Tuberculosis-Related Malnutrition: Public Health ImplicationsLies Ter Beek, Jan-Willem C Alffenaar, Mathieu S Bolhuis, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis TreatmentLina Keutzer, Laurynas Mockeliunas, Marieke G G Sturkenboom, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 14, 2023
Update of drug-resistant tuberculosis treatment guidelines: A turning pointElisa Vanino, Bianca Granozzi, Onno W Akkerman, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 17, 2025
Quantification of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor and their active metabolites in plasma using UHPLC-MS/MS: Doors open to the application of therapeutic drug monitoring in cystic fibrosis treatmentA Mireille A Wessels, Femke A Elzinga, Gerard H Koppelman, et al.
Pageof 12

Showing results (11-20 of 115) with videos related to

Sort By:
Pageof 12
Infection|April 8, 2024
The agreement between bronchoalveolar lavage, bronchial wash and sputum culture: a retrospective studyAnne-Eva Post, Erik Bathoorn, Douwe F Postma, et al.
The European Respiratory Journal|September 14, 2019
Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the NetherlandsFajri Gafar, Natasha Van't Boveneind-Vrubleuskaya, Onno W Akkerman, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 31, 2020
Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?Jan-Willem C Alffenaar, Onno W Akkerman, Hannah Yejin Kim, et al.
Antimicrobial Resistance and Infection Control|July 25, 2019
Treatment outcomes of drug-resistant tuberculosis in the Netherlands, 2005-2015Ivan S Pradipta, Natasha Van't Boveneind-Vrubleuskaya, Onno W Akkerman, et al.
Antimicrobial Agents and Chemotherapy|December 24, 2013
Strategy to limit sampling of antituberculosis drugs instead of determining concentrations at two hours postingestion in relation to treatment responseOnno W Akkerman, Richard van Altena, Mathieu S Bolhuis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis TreatmentMarieke G G Sturkenboom, Noviana Simbar, Onno W Akkerman, et al.
The Journal of Infectious Diseases|March 6, 2019
Tuberculosis-Related Malnutrition: Public Health ImplicationsLies Ter Beek, Jan-Willem C Alffenaar, Mathieu S Bolhuis, et al.
Pharmaceuticals (Basel, Switzerland)|November 25, 2023
Derivation and Clinical Utility of Safety Targets for Linezolid-Related Adverse Events in Drug-Resistant Tuberculosis TreatmentLina Keutzer, Laurynas Mockeliunas, Marieke G G Sturkenboom, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|March 14, 2023
Update of drug-resistant tuberculosis treatment guidelines: A turning pointElisa Vanino, Bianca Granozzi, Onno W Akkerman, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|April 17, 2025
Quantification of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor and their active metabolites in plasma using UHPLC-MS/MS: Doors open to the application of therapeutic drug monitoring in cystic fibrosis treatmentA Mireille A Wessels, Femke A Elzinga, Gerard H Koppelman, et al.
Pageof 12